Year |
Citation |
Score |
2023 |
Tian GL, Hsieh CJ, Taylor M, Lee JY, Riad AA, Luedtke RR, Mach RH. Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D and D receptors. European Journal of Medicinal Chemistry. 261: 115751. PMID 37688938 DOI: 10.1016/j.ejmech.2023.115751 |
0.611 |
|
2023 |
Estrada-Sánchez AM, Rangel-Barajas C, Howe AG, Barton SJ, Mach RH, Luedtke RR, Rebec GV. Selective Activation of D3 Dopamine Receptors Ameliorates DOI-Induced Head Twitching Accompanied by Changes in Corticostriatal Processing. International Journal of Molecular Sciences. 24. PMID 37298250 DOI: 10.3390/ijms24119300 |
0.57 |
|
2023 |
Gao RD, Taylor M, McInnis T, Chen Z, Gori SS, LaPorte HM, Siegler MA, Neisewander JL, Mach RH, Singh M, Slusher BS, Rais R, Luedtke RR, Tsukamoto T. Synthesis and Pharmacological Characterization of a Difluorinated Analogue of Reduced Haloperidol as a Sigma-1 Receptor Ligand. Acs Chemical Neuroscience. PMID 36780706 DOI: 10.1021/acschemneuro.2c00791 |
0.558 |
|
2022 |
Kim HY, Lee JY, Hsieh CJ, Taylor M, Luedtke RR, Mach RH. Design and Synthesis of Conformationally Flexible Scaffold as Bitopic Ligands for Potent D-Selective Antagonists. International Journal of Molecular Sciences. 24. PMID 36613875 DOI: 10.3390/ijms24010432 |
0.749 |
|
2021 |
Lee B, Taylor M, Griffin SA, McInnis T, Sumien N, Mach RH, Luedtke RR. Evaluation of Substituted -Phenylpiperazine Analogs as D3 vs. D2 Dopamine Receptor Subtype Selective Ligands. Molecules (Basel, Switzerland). 26. PMID 34073405 DOI: 10.3390/molecules26113182 |
0.766 |
|
2021 |
Hayatshahi HS, Luedtke RR, Taylor M, Chen PJ, Blass BE, Liu J. Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes. Journal of Chemical Information and Modeling. PMID 33988991 DOI: 10.1021/acs.jcim.1c00036 |
0.597 |
|
2021 |
Hsieh CJ, Riad A, Lee JY, Sahlholm K, Xu K, Luedtke RR, Mach RH. Interaction of Ligands for PET with the Dopamine D3 Receptor: In Silico and In Vitro Methods. Biomolecules. 11. PMID 33918451 DOI: 10.3390/biom11040529 |
0.485 |
|
2020 |
Ågren R, Zeberg H, Maciej Stępniewski T, Free RB, Reilly SW, Luedtke RR, Århem P, Ciruela F, Sibley DR, Mach RH, Selent J, Nilsson J, Sahlholm K. A ligand with two modes of interaction with the dopamine D2 receptor - An induced-fit mechanism of insurmountable antagonism. Acs Chemical Neuroscience. PMID 32865974 DOI: 10.1021/Acschemneuro.0C00477 |
0.536 |
|
2019 |
Chen PJ, Taylor M, Griffin SA, Amani A, Hayatshahi H, Korzekwa K, Ye M, Mach RH, Liu J, Luedtke RR, Gordon JC, Blass BE. Design, synthesis, and evaluation of N-(4-(4-phenyl piperazin-1-yl)butyl)-4-(thiophen-3-yl)benzamides as selective dopamine D receptor ligands. Bioorganic & Medicinal Chemistry Letters. PMID 31387791 DOI: 10.1016/J.Bmcl.2019.07.020 |
0.652 |
|
2019 |
Reilly SW, Riad AA, Hsieh CJ, Sahlholm K, Jacome DA, Griffin S, Taylor M, Weng CC, Xu K, Kirschner N, Luedtke RR, Parry C, Malhotra S, Karanicolas J, Mach RH. Leveraging a Low Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D3 Receptor (D3R) Ligand Promiscuity Across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs). Journal of Medicinal Chemistry. PMID 31021617 DOI: 10.1021/Acs.Jmedchem.9B00412 |
0.667 |
|
2019 |
Powell GL, Bonadonna JP, Vannan A, Xu K, Mach RH, Luedtke RR, Neisewander JL. Retraction notice to "Dopamine Ds3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors" [Pharmacology, Biochemistry and Behavior 171 (2018) 46-53]. Pharmacology, Biochemistry, and Behavior. 176: 111. PMID 30616777 DOI: 10.1016/J.Pbb.2018.12.011 |
0.351 |
|
2018 |
Powell GL, Bonadonna JP, Vannan A, Mach RH, Luedtke RR, Neisewander JL. Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors. Pharmacology, Biochemistry, and Behavior. PMID 30308214 DOI: 10.1016/J.Pbb.2018.10.002 |
0.573 |
|
2018 |
Hayatshahi HS, Xu K, Griffin SA, Taylor M, Mach RH, Liu J, Luedtke RR. Analogs of Arylamide Phenylpiperazine Ligands to Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity. Acs Chemical Neuroscience. PMID 30010318 DOI: 10.1021/Acschemneuro.8B00142 |
0.72 |
|
2018 |
Powell GL, Bonadonna JP, Vannan A, Xu K, Mach RH, Luedtke RR, Neisewander JL. Dopamine Ds3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors. Pharmacology, Biochemistry, and Behavior. PMID 29807065 DOI: 10.1016/J.Pbb.2018.05.015 |
0.533 |
|
2017 |
Reilly SW, Griffin S, Taylor M, Sahlholm K, Weng CC, Xu K, Jacome DA, Luedtke RR, Mach RH. Highly Selective Dopamine D3 Receptor Antagonists with Arylated Diazaspiro Alkane Cores. Journal of Medicinal Chemistry. PMID 29125762 DOI: 10.1021/Acs.Jmedchem.7B01248 |
0.625 |
|
2017 |
Mach RH, Luedtke RR. Challenges in the Development of Dopamine D2- and D3-selective Radiotracers for PET Imaging Studies. Journal of Labelled Compounds & Radiopharmaceuticals. PMID 28857231 DOI: 10.1002/Jlcr.3558 |
0.673 |
|
2017 |
Salvatore MF, Terrebonne J, Cantu MA, McInnis TR, Venable K, Kelley P, Kasanga EA, Latimer B, Owens CL, Pruett BS, Yu Y, Luedtke R, Forster MJ, Sumien N, Ingram DK. Dissociation of striatal dopamine and tyrosine hydroxylase expression from aging-related motor decline: evidence from calorie restriction intervention. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. PMID 28637176 DOI: 10.1093/Gerona/Glx119 |
0.335 |
|
2017 |
Bonadonna JP, Powell G, Carlson AK, Mendoza R, Mach RH, Luedtke RR, Neisewander JL. Effect of a dopamine D3 receptor partial agonist on cocaine-induced locomotion and self-administration Drug and Alcohol Dependence. 171: e23. DOI: 10.1016/J.Drugalcdep.2016.08.077 |
0.504 |
|
2016 |
Malik M, Rangel-Barajas C, Mach RH, Luedtke RR. The Effect of the Sigma-1 Receptor Selective Compound LS-1-137 on the DOI-Induced Head Twitch Response in Mice. Pharmacology, Biochemistry, and Behavior. PMID 27397487 DOI: 10.1016/J.Pbb.2016.07.001 |
0.677 |
|
2015 |
Luedtke RR, Rangel-Barajas C, Malik M, Reichert DE, Mach RH. Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics. Current Pharmaceutical Design. 21: 3700-24. PMID 26205291 DOI: 10.2174/1381612821666150724100830 |
0.756 |
|
2015 |
Rangel-Barajas C, Malik M, Mach RH, Luedtke RR. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds. Neuropharmacology. 93: 179-90. PMID 25698528 DOI: 10.1016/J.Neuropharm.2014.10.030 |
0.772 |
|
2015 |
Malik M, Rangel-Barajas C, Sumien N, Su C, Singh M, Chen Z, Huang RQ, Meunier J, Maurice T, Mach RH, Luedtke RR. The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice. British Journal of Pharmacology. 172: 2519-31. PMID 25573298 DOI: 10.1111/Bph.13076 |
0.505 |
|
2015 |
Peng X, Wang Q, Mishra Y, Xu J, Reichert DE, Malik M, Taylor M, Luedtke RR, Mach RH. Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands. Bioorganic & Medicinal Chemistry Letters. 25: 519-23. PMID 25556097 DOI: 10.1016/J.Bmcl.2014.12.023 |
0.77 |
|
2014 |
Ananthan S, Saini SK, Zhou G, Hobrath JV, Padmalayam I, Zhai L, Bostwick JR, Antonio T, Reith ME, McDowell S, Cho E, McAleer L, Taylor M, Luedtke RR. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. Journal of Medicinal Chemistry. 57: 7042-60. PMID 25126833 DOI: 10.1021/Jm500801R |
0.752 |
|
2014 |
Rangel-Barajas C, Malik M, Taylor M, Neve KA, Mach RH, Luedtke RR. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand. Journal of Neurochemistry. 131: 418-31. PMID 25041389 DOI: 10.1111/Jnc.12825 |
0.769 |
|
2014 |
Rangel-Barajas C, Malik M, Vangveravong S, Mach RH, Luedtke RR. Pharmacological modulation of abnormal involuntary DOI-induced head twitch response in male DBA/2J mice: I. Effects of D2/D3 and D2 dopamine receptor selective compounds. Neuropharmacology. 83: 18-27. PMID 24680675 DOI: 10.1016/J.Neuropharm.2014.03.003 |
0.759 |
|
2013 |
Tu Z, Li S, Li A, Taylor M, Ho D, Malik M, Luedtke RR, Mach RH. Synthesis and in vitro pharmacological evaluation of indolyl carboxylic amide analogues as D3 dopamine receptor selective ligands. Medchemcomm. 4: 1283-1289. PMID 24156012 DOI: 10.1039/C3Md00098B |
0.772 |
|
2013 |
Cheung TH, Loriaux AL, Weber SM, Chandler KN, Lenz JD, Schaan RF, Mach RH, Luedtke RR, Neisewander JL. Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55. The Journal of Pharmacology and Experimental Therapeutics. 347: 410-23. PMID 24018640 DOI: 10.1124/Jpet.112.202911 |
0.316 |
|
2013 |
Huang R, Griffin SA, Taylor M, Vangveravong S, Mach RH, Dillon GH, Luedtke RR. The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition. Pharmacology. 92: 84-9. PMID 23942137 DOI: 10.1159/000351971 |
0.745 |
|
2013 |
Li A, Mishra Y, Malik M, Wang Q, Li S, Taylor M, Reichert DE, Luedtke RR, Mach RH. Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands. Bioorganic & Medicinal Chemistry. 21: 2988-98. PMID 23618707 DOI: 10.1016/J.Bmc.2013.03.074 |
0.762 |
|
2013 |
Newman AH, Banala AK, Donthamsetti P, Cao J, Michino M, Luedtke RR, Javitch JA, Shi L. Drug Design for Addiction - Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 181-182. DOI: 10.1016/B978-0-12-800044-1.00163-X |
0.57 |
|
2012 |
Luedtke RR, Mishra Y, Wang Q, Griffin SA, Bell-Horner C, Taylor M, Vangveravong S, Dillon GH, Huang RQ, Reichert DE, Mach RH. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds. Acs Chemical Neuroscience. 3: 1050-62. PMID 23259040 DOI: 10.1021/Cn300142Q |
0.803 |
|
2012 |
Newman AH, Beuming T, Banala AK, Donthamsetti P, Pongetti K, LaBounty A, Levy B, Cao J, Michino M, Luedtke RR, Javitch JA, Shi L. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. Journal of Medicinal Chemistry. 55: 6689-99. PMID 22632094 DOI: 10.1021/Jm300482H |
0.583 |
|
2012 |
Luedtke RR, Perez E, Yang SH, Liu R, Vangveravong S, Tu Z, Mach RH, Simpkins JW. Neuroprotective effects of high affinity Σ1 receptor selective compounds. Brain Research. 1441: 17-26. PMID 22285434 DOI: 10.1016/J.Brainres.2011.12.047 |
0.713 |
|
2011 |
Wang W, Cui J, Lu X, Padakanti PK, Xu J, Parsons SM, Luedtke RR, Rath NP, Tu Z. Synthesis and in vitro biological evaluation of carbonyl group-containing analogues for σ1 receptors. Journal of Medicinal Chemistry. 54: 5362-72. PMID 21732626 DOI: 10.1021/Jm200203F |
0.435 |
|
2011 |
Tu Z, Li S, Xu J, Chu W, Jones LA, Luedtke RR, Mach RH. Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain. Nuclear Medicine and Biology. 38: 725-39. PMID 21718948 DOI: 10.1016/J.Nucmedbio.2011.01.002 |
0.541 |
|
2011 |
Vangveravong S, Zhang Z, Taylor M, Bearden M, Xu J, Cui J, Wang W, Luedtke RR, Mach RH. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound. Bioorganic & Medicinal Chemistry. 19: 3502-11. PMID 21536445 DOI: 10.1016/J.Bmc.2011.04.021 |
0.669 |
|
2011 |
Banala AK, Levy BA, Khatri SS, Furman CA, Roof RA, Mishra Y, Griffin SA, Sibley DR, Luedtke RR, Newman AH. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. Journal of Medicinal Chemistry. 54: 3581-94. PMID 21495689 DOI: 10.1021/Jm200288R |
0.747 |
|
2011 |
Tu Z, Li S, Cui J, Xu J, Taylor M, Ho D, Luedtke RR, Mach RH. Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands. Journal of Medicinal Chemistry. 54: 1555-64. PMID 21348515 DOI: 10.1021/Jm101323B |
0.761 |
|
2011 |
Blaylock BL, Gould RW, Banala A, Grundt P, Luedtke RR, Newman AH, Nader MA. Influence of cocaine history on the behavioral effects of Dopamine D(3) receptor-selective compounds in monkeys. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 1104-13. PMID 21289600 DOI: 10.1038/Npp.2010.248 |
0.407 |
|
2011 |
Mach RH, Tu Z, Xu J, Li S, Jones LA, Taylor M, Luedtke RR, Derdeyn CP, Perlmutter JS, Mintun MA. Endogenous dopamine (DA) competes with the binding of a radiolabeled D3 receptor partial agonist in vivo: A positron emission tomography study Synapse. 65: 724-732. PMID 21132811 DOI: 10.1002/Syn.20891 |
0.679 |
|
2011 |
Karimi M, Moerlein SM, Videen TO, Luedtke RR, Taylor M, Mach RH, Perlmutter JS. Decreased striatal dopamine receptor binding in primary focal dystonia: A D2 or D3 defect? Movement Disorders. 26: 100-106. PMID 20960437 DOI: 10.1002/Mds.23401 |
0.687 |
|
2011 |
Riddle LR, Kumar R, Griffin SA, Grundt P, Newman AH, Luedtke RR. Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats. Neuropharmacology. 60: 284-94. PMID 20850462 DOI: 10.1016/j.neuropharm.2010.09.011 |
0.517 |
|
2010 |
Wang Q, Mach RH, Luedtke RR, Reichert DE. Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods. Journal of Chemical Information and Modeling. 50: 1970-85. PMID 20936866 DOI: 10.1021/Ci1002747 |
0.571 |
|
2010 |
Silvano E, Millan MJ, Mannoury la Cour C, Han Y, Duan L, Griffin SA, Luedtke RR, Aloisi G, Rossi M, Zazzeroni F, Javitch JA, Maggio R. The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors. Molecular Pharmacology. 78: 925-34. PMID 20702763 DOI: 10.1124/Mol.110.065755 |
0.699 |
|
2010 |
Vangveravong S, Taylor M, Xu J, Cui J, Calvin W, Babic S, Luedtke RR, Mach RH. Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorganic & Medicinal Chemistry. 18: 5291-300. PMID 20542439 DOI: 10.1016/J.Bmc.2010.05.052 |
0.728 |
|
2010 |
Xu J, Hassanzadeh B, Chu W, Tu Z, Jones LA, Luedtke RR, Perlmutter JS, Mintun MA, Mach RH. [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)- butyl)benzamide: A selective radioligand for dopamine D3 receptors. II. Quantitative analysis of dopamine D3 and D2 receptor density ratio in the caudate-putamen Synapse. 64: 449-459. PMID 20175227 DOI: 10.1002/Syn.20748 |
0.683 |
|
2010 |
Taylor M, Grundt P, Griffin SA, Newman AH, Luedtke RR. Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways. Synapse (New York, N.Y.). 64: 251-66. PMID 19924694 DOI: 10.1002/syn.20725 |
0.71 |
|
2009 |
Weber M, Chang WL, Durbin JP, Park PE, Luedtke RR, Mach RH, Swerdlow NR. Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44. Pharmacology, Biochemistry, and Behavior. 93: 141-7. PMID 19426754 DOI: 10.1016/J.Pbb.2009.04.022 |
0.634 |
|
2009 |
Xu J, Chu W, Tu Z, Jones LA, Luedtke RR, Perlmutter JS, Mintun MA, Mach RH. [3H]4-(dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl]benzamide, a selective radioligand for dopamine D3 receptors. I. In vitro characterization Synapse. 63: 717-728. PMID 19425052 DOI: 10.1002/Syn.20652 |
0.698 |
|
2009 |
Kumar R, Riddle LR, Griffin SA, Chu W, Vangveravong S, Neisewander J, Mach RH, Luedtke RR. Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats Neuropharmacology. 56: 956-969. PMID 19371586 DOI: 10.1016/J.Neuropharm.2009.01.019 |
0.696 |
|
2009 |
Kumar R, Riddle L, Griffin SA, Grundt P, Newman AH, Luedtke RR. Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology. 56: 944-55. PMID 19371585 DOI: 10.1016/j.neuropharm.2009.01.020 |
0.463 |
|
2009 |
Newman AH, Grundt P, Cyriac G, Deschamps JR, Taylor M, Kumar R, Ho D, Luedtke RR. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. Journal of Medicinal Chemistry. 52: 2559-70. PMID 19331412 DOI: 10.1021/jm900095y |
0.726 |
|
2008 |
Paul NM, Taylor M, Kumar R, Deschamps JR, Luedtke RR, Newman AH. Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol. Journal of Medicinal Chemistry. 51: 6095-109. PMID 18774793 DOI: 10.1021/jm800532x |
0.588 |
|
2007 |
Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. Journal of Medicinal Chemistry. 50: 4135-46. PMID 17672446 DOI: 10.1021/jm0704200 |
0.735 |
|
2007 |
Grundt P, Husband SL, Luedtke RR, Taylor M, Newman AH. Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR. Bioorganic & Medicinal Chemistry Letters. 17: 745-9. PMID 17095222 DOI: 10.1016/j.bmcl.2006.10.076 |
0.686 |
|
2007 |
Corvol JC, Valjent E, Pascoli V, Robin A, Stipanovich A, Luedtke RR, Belluscio L, Girault JA, Hervé D. Quantitative changes in Galphaolf protein levels, but not D1 receptor, alter specifically acute responses to psychostimulants. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 1109-21. PMID 17063155 DOI: 10.1038/Sj.Npp.1301230 |
0.48 |
|
2006 |
Vangveravong S, McElveen E, Taylor M, Xu J, Tu Z, Luedtke RR, Mach RH. Synthesis and characterization of selective dopamine D2 receptor antagonists. Bioorganic & Medicinal Chemistry. 14: 815-25. PMID 16288878 DOI: 10.1016/J.Bmc.2005.09.008 |
0.78 |
|
2005 |
Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Journal of Medicinal Chemistry. 48: 839-48. PMID 15689168 DOI: 10.1021/Jm049465G |
0.757 |
|
2005 |
Chu W, Tu Z, McElveen E, Xu J, Taylor M, Luedtke RR, Mach RH. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorganic & Medicinal Chemistry. 13: 77-87. PMID 15582454 DOI: 10.1016/J.Bmc.2004.09.054 |
0.559 |
|
2004 |
Chen J, Rusnak M, Luedtke RR, Sidhu A. D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. The Journal of Biological Chemistry. 279: 39317-30. PMID 15247297 DOI: 10.1074/Jbc.M403891200 |
0.538 |
|
2004 |
Mach RH, Huang Y, Freeman RA, Wu L, Vangveravong S, Luedtke RR. Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. Bioorganic & Medicinal Chemistry Letters. 14: 195-202. PMID 14684327 DOI: 10.1016/J.Bmcl.2003.09.083 |
0.764 |
|
2004 |
Luedtke RR, Bell-Horner CL, Volk M, Reinecke MG, Dillon GH. Pharmacological survey of medicinal plants for activity at ligand-gated ion channels: Selective interaction with 5-HT3 receptors Pharmaceutical Biology. 42: 73-82. DOI: 10.1080/13880200490505654 |
0.42 |
|
2003 |
Rahman Z, Schwarz J, Gold SJ, Zachariou V, Wein MN, Choi KH, Kovoor A, Chen CK, DiLeone RJ, Schwarz SC, Selley DE, Sim-Selley LJ, Barrot M, Luedtke RR, Self D, et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron. 38: 941-52. PMID 12818179 DOI: 10.1016/S0896-6273(03)00321-0 |
0.546 |
|
2003 |
Newman AH, Cao J, Bennett CJ, Robarge MJ, Freeman RA, Luedtke RR. N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl}arylcarboxamides as novel dopamine D3 receptor antagonists Bioorganic and Medicinal Chemistry Letters. 13: 2179-2183. PMID 12798330 DOI: 10.1016/S0960-894X(03)00389-5 |
0.737 |
|
2003 |
Mach RH, Huang Y, Freeman RA, Wu L, Blair S, Luedtke RR. Synthesis of 2-(5-bromo-2,3-dimethoxyphenyl)-5-(aminomethyl)-1H-pyrrole analogues and their binding affinities for dopamine D2, D3, and D4 receptors. Bioorganic & Medicinal Chemistry. 11: 225-33. PMID 12470717 DOI: 10.1016/S0968-0896(02)00341-3 |
0.764 |
|
2003 |
Luedtke RR, Freeman RA, Volk M, Arfan M, Reinecke MG. Pharmacological survey of medicinal plants for activity at dopamine receptor subtypes. II. Screen for binding activity at the D1 and D2 dopamine receptor subtypes Pharmaceutical Biology. 41: 45-58. DOI: 10.1076/Phbi.41.1.45.14695 |
0.711 |
|
2002 |
Luedtke RR, Freeman RA, Martin MW, Bastien JW, Zalles-Asin J, Reinecke MG. Pharmacological survey of medicinal plants for activity at dopamine receptor subtypes. I. Activation of D1-like receptor linked adenylyl cyclase Pharmaceutical Biology. 40: 315-325. DOI: 10.1076/phbi.40.4.315.8463 |
0.482 |
|
2001 |
Huang Y, Luedtke RR, Freeman RA, Wu L, Mach RH. Synthesis of 2-(2,3-dimethoxyphenyl)-4-(aminomethyl)imidazole analogues and their binding affinities for dopamine D2 and D3 receptors Bioorganic and Medicinal Chemistry. 9: 3113-3122. PMID 11711286 DOI: 10.1016/S0968-0896(01)00175-4 |
0.764 |
|
2001 |
Martin MW, Scott AW, Johnston DE, Griffin S, Luedtke RR. Typical antipsychotics exhibit inverse agonist activity at rat dopamine D1-like receptors expressed in Sf9 cells European Journal of Pharmacology. 420: 73-82. PMID 11408027 DOI: 10.1016/S0014-2999(01)00982-7 |
0.636 |
|
2001 |
Huang Y, Luedtke RR, Freeman RA, Wu L, Mach RH. Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands Journal of Medicinal Chemistry. 44: 1815-1826. PMID 11356115 DOI: 10.1021/Jm0100077 |
0.72 |
|
2000 |
Luedtke RR, Freeman RA, Boundy VA, Martin MW, Huang Y, Mach RH. Characterization of 125I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors Synapse. 38: 438-449. PMID 11044891 DOI: 10.1002/1098-2396(20001215)38:4<438::Aid-Syn9>3.0.Co;2-5 |
0.738 |
|
1999 |
Nader MA, Green KL, Luedtke RR, Mach RH. The effects of benzamide analogues on cocaine self-administration in rhesus monkeys. Psychopharmacology. 147: 143-52. PMID 10591881 DOI: 10.1007/S002130051154 |
0.47 |
|
1999 |
Luedtke RR, Griffin SA, Conroy SS, Jin X, Pinto A, Sesack SR. Immunoblot and immunohistochemical comparison of murine monoclonal antibodies specific for the rat D1a and D1b dopamine receptor subtypes. Journal of Neuroimmunology. 101: 170-87. PMID 10580800 DOI: 10.1016/S0165-5728(99)00142-3 |
0.52 |
|
1999 |
Hammond PS, Cheney JT, Johnston DE, Ehrenkaufer RL, Luedtke RR, Mach RH. Synthesis, in vitro dopamine D2 and D3 receptor binding and quantitative structure-activity studies on substituted 2,3-dimethoxy-N-(1- benzyl-4-piperidinyl)benzamides and related compounds Medicinal Chemistry Research. 9: 35-49. |
0.753 |
|
1999 |
Mach RH, Hammond PS, Huang Y, Yang B, Xu Y, Cheney JT, Freeman R, Luedtke RR. Structure-activity relationship studies of N-(9-benzyl)-9- azabicyclo[3.3.1]nonan-3-β-yl benzamide analogues for dopamine D2 and D3 receptors Medicinal Chemistry Research. 9: 355-373. |
0.715 |
|
1998 |
Yang B, Johnston DE, Luedtke RR, Hammond PS, Mach RH. Synthesis and in vitro binding of N-alkyl-2,3- dimethoxy[3.3.1]azabicyclononane benzamides at dopamine D2 and D3 receptors Medicinal Chemistry Research. 8: 115-131. |
0.738 |
|
1996 |
Mach RH, Nader MA, Ehrenkaufer RL, Line SW, Smith CR, Luedtke RR, Kung MP, Kung HF, Lyons D, Morton TE. Comparison of two fluorine-18 labeled benzamide derivatives that bind reversibly to dopamine D2 receptors: in vitro binding studies and positron emission tomography. Synapse (New York, N.Y.). 24: 322-33. PMID 10638823 DOI: 10.1002/(Sici)1098-2396(199612)24:4<322::Aid-Syn2>3.0.Co;2-F |
0.658 |
|
1996 |
Ward AS, Li DH, Luedtke RR, Emmett-Oglesby MW. Variations in cocaine self-administration by inbred rat strains under a progressive-ratio schedule. Psychopharmacology. 127: 204-12. PMID 8912398 DOI: 10.1007/s002130050078 |
0.309 |
|
1995 |
Essman WD, Luedtke RR, McGonigle P, Lucky I. Variations in the behavioral responses to apomorphine in different strains of rats. Behavioural Pharmacology. 6: 4-15. PMID 11224306 |
0.402 |
|
1995 |
Scott AW, Griffin SA, Luedtke RR. Genetic polymorphisms at the rat and murine loci coding for dopamine D2-like receptors Molecular Brain Research. 29: 347-357. PMID 7609622 DOI: 10.1016/0169-328X(94)00271-F |
0.582 |
|
1993 |
Boundy VA, Luedtke RR, Artymyshyn RP, Filtz TM, Molinoff PB. Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides. Molecular Pharmacology. 43: 666-76. PMID 8502224 |
0.626 |
|
1993 |
Boundy VA, Luedtke RR, Gallitano AL, Smith JE, Filtz TM, Kallen RG, Molinoff PB. Expression and characterization of the rat D3 dopamine receptor: pharmacologic properties and development of antibodies. The Journal of Pharmacology and Experimental Therapeutics. 264: 1002-11. PMID 8437101 |
0.613 |
|
1993 |
Mach RH, Elder ST, Morton TE, Nowak PA, Evora PH, Scripko JG, Luedtke RR, Unsworth CD, Filtz T, Rao AV, Molinoff PB, Ehrenkaufer RLE. The use of [18F]4-fluorobenzyl iodide (FBI) in PET radiotracer synthesis: Model alkylation studies and its application in the design of dopamine D1 and D2 receptor-based imaging agents Nuclear Medicine and Biology. 20: 777-794. PMID 8401379 DOI: 10.1016/0969-8051(93)90165-Q |
0.392 |
|
1993 |
Mach RH, Luedtke RR, Unsworth CD, Boundy VA, Nowak PA, Scripko JG, Elder ST, Jackson JR, Hoffman PL, Evora PH. 18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography. Journal of Medicinal Chemistry. 36: 3707-20. PMID 8246241 DOI: 10.1021/Jm00075A028 |
0.533 |
|
1993 |
Boundy VA, Luedtke RR, Molinoff PB. Development of polyclonal anti-D2 dopamine receptor antibodies to fusion proteins: inhibition of D2 receptor-G protein interaction. Journal of Neurochemistry. 60: 2181-91. PMID 8098355 |
0.613 |
|
1992 |
Mach RH, Jackson JR, Luedtke RR, Ivins KJ, Molinoff PB, Ehrenkaufer RL. Effect of N-alkylation on the affinities of analogues of spiperone for dopamine D2 and serotonin 5-HT2 receptors. Journal of Medicinal Chemistry. 35: 423-30. PMID 1531364 DOI: 10.1021/Jm00081A002 |
0.6 |
|
1992 |
Artymyshyn RP, Ivins KJ, Monks BR, Luedtke RR, Molinoff PB. Quantitation of isotypes of D2 receptors using solution hybridization. Neurochemistry International. 20: 189S-195S. PMID 1365424 DOI: 10.1016/0197-0186(92)90237-L |
0.383 |
|
1992 |
Luedtke RR, Artymyshyn RP, Monks BR, Molinoff PB. Comparison of the expression, transcription and genomic organization of D2 dopamine receptors in outbred and inbred strains of rat. Brain Research. 584: 45-54. PMID 1355393 DOI: 10.1016/0006-8993(92)90876-B |
0.486 |
|
1991 |
Ivins KJ, Luedtke RR, Artymyshyn RP, Molinoff PB. Regulation of dopamine D2 receptors in a novel cell line (SUP1). Molecular Pharmacology. 39: 531-9. PMID 1708089 |
0.631 |
|
1989 |
Schonwetter BS, Luedtke RR, Kung MP, Billings J, Kung HF, Molinoff PB. Characterization of membrane-bound and soluble D2 receptors in canine caudate using [125I]IBZM. The Journal of Pharmacology and Experimental Therapeutics. 250: 110-6. PMID 2526213 |
0.597 |
|
1988 |
Luedtke RR, Korner M, Neve KA, Molinoff PB. Monoclonal antibodies with high affinity for spiroperidol. Journal of Neurochemistry. 50: 1253-62. PMID 2964511 DOI: 10.1111/J.1471-4159.1988.Tb10602.X |
0.389 |
|
1987 |
Luedtke RR, Molinoff PB. Characterization of binding sites for [3H]spiroperidol. Biochemical Pharmacology. 36: 3255-64. PMID 2959288 DOI: 10.1016/0006-2952(87)90642-3 |
0.356 |
|
Show low-probability matches. |